UBS Downgrades Treace Medical Concepts to Neutral, Lowers Price Target to $6.5
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy has downgraded Treace Medical Concepts (NASDAQ:TMCI) from Buy to Neutral and lowered the price target from $16 to $6.5.
May 16, 2024 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
UBS analyst Danielle Antalffy downgraded Treace Medical Concepts from Buy to Neutral and significantly lowered the price target from $16 to $6.5.
The downgrade from Buy to Neutral and the significant reduction in the price target from $16 to $6.5 by UBS is likely to negatively impact the stock price of Treace Medical Concepts in the short term. Such downgrades often lead to selling pressure as investors adjust their expectations.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100